US/UK/Canada

Share

Contacts

  • BIOINVENT
    Sölvegatan 41 223 70 LUND
    +46 46 286 85 50
    +46 46 211 08 06
    http://www.bioinvent.com

    • Quotes

    FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly attracting interest as revealed by the recent deals in the field. The development of BI-1808 is supported by an impressive set of preclinical data and is one of three BioInvent lead candidates in clinical development.
    Martin Welschof, CEO BioInvent International
    The data on BI-1607 are very exciting and provide proof-of-concept of its ability to enhance anti-cancer immunity, illustrated by its ability to boost activity and overcome resistance to CTLA-4-based therapy. We are looking forward to advancing BI-1607 into clinical development and expect to submit a clinical trial application during H2 2021. It will be BioInvent’s fourth drug candidate in clinical development, further demonstrating the strength and productivity of our technology platform.
    Martin Welschof, CEO
    Pick a time period -
    Tags ( Active)

    BioStock: BioInvent anticipates strong influx of clinical data

    BioInvent achieved solid progress throughout the third quarter, and CEO Martin Welschof anticipates a data-rich conclusion to 2024 that will further strengthen the company.– Looking ahead to next year, we expect BioInvent’s strong momentum to persist, with seven essential data readouts across four drug candidates in clinical development.Read the article at biostock.se: https://www.biostock.se/en/2024/10/bioinvent-anticipates-strong-influx-of-clinical-data/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CMO comments on the ESMO presentation

    BioInvent and Transgene presented promising phase I/IIa data on BT-001 at ESMO in Barcelona this weekend. BioStock contacted BioInvent’s CMO, Andres McAllister, who is attending the conference, to discuss these findings and other recent advancements.Read the interview with Andres McAllister at biostock.se: https://www.biostock.se/en/2024/09/bioinvents-cmo-comments-on-the-esmo-presentation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent makes a strong entrance at ESMO in Barcelona

    BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a monotherapy. Additionally, BioInvent and Transgene are set to present encouraging initial phase I/IIa data on BT-001 at ESMO 2024. BI-1910 will also be featured in a poster presentation at the same conference.Read the article at biostock.se: https://www.biostock.se/en/2024/09/bioinvent-makes-a-strong-entrance-at-esmo-in-barcelona/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent anticipates a continued data-rich 2024

    With cash reserves surpassing one billion SEK, providing significant operational flexibility, and anticipating results from several of its clinical programs, BioInvent is entering an eventful autumn. In the H1 interim report, CEO Martin Welschof conveys optimism about the company’s future developing novel cancer treatments.– The second quarter was very busy and highly productive, and we will continue this momentum into the second half of the year.Read the article at biostock.se: https://www.biostock.se/en/2024/09/bioinvent-anticipates-a-continued-data-rich-2024/ This is a press

    BioStock: BioInvent and MSD to evaluate new metastatic melanoma treatment

    BioInvent, known for its innovative cancer immunotherapies, is expanding its partnership with MSD to test BI-1607 in combination with ipilimumab and KEYTRUDA in a phase II trial for metastatic melanoma. The phase II study aims to enhance the efficacy of these existing treatments while reducing toxicity, potentially offering a more tolerable and effective treatment regimen.Read the article at biostock.se: BioInvent and MSD to evaluate new metastatic melanoma treatment 

    BioStock: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

    BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent’s candidates hold great promise for the future of immuno-oncology.Read the article at biostock.se: Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0” - BioStock 

    BioStock: BioInvent to present promising clinical data at ASCO and EHA

    In the coming weeks, BioInvent is set to present three significant data sets at the American Society for Clinical Oncology’s (ASCO) annual congress and the European Hematology Association’s (EHA) annual meeting. At ASCO, BioInvent will showcase advancements with BI-1808 monotherapy and BI-1206 in combination with Keytruda. At EHA, promising data on BI-2106 will be presented to the expert community.Read the article at biostock.se: https://www.biostock.se/en/2024/05/bioinvent-to-present-promising-clinical-data-at-asco-and-eha/ This is a press release from BioStock - Connecting

    BioStock: BioInvent selected to present at ASCO in Chicago

    BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-selected-to-present-at-asco-in-chicago/ This is a press release from

    BioStock: BioInvent deepens collaboration with MSD

    BioInvent has signed a new clinical collaboration and supply agreement with MSD. The agreement covers the evaluation of BioInvent’s anti-TNFR2 antibody BI-1910 in combination with MSD’s Keytruda in the second part of a phase I/IIa study in solid tumours. The monotherapy part of the study has been ongoing since December, and the first results are expected by year-end 2024.Read the full article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-deepens-collaboration-with-msd/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO comments on the study success in China

    BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin’s lymphoma. BioStock reached out to BioInvent’s CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.Read the full interview with Martin Welschof at biostock.se: https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/ This is a press

    BioStock: BioInvent expects data from seven clinical studies in 2024

    BioInvent entered 2024 with a solid financial reserve of 1358 SEK million, equivalent to 132 million USD. Anticipating significant milestones, the company is poised to release data from seven clinical studies throughout the year. Thus building on the momentum generated in 2023 with progress across six clinical programmes.Read the article at biostock.se: https://www.biostock.se/en/2024/01/bioinvent-expects-data-from-seven-clinical-studies-in-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO: “This year we made unprecedented progress”

    2023 has undoubtedly been one of the most successful for BioInvent, if not the most successful. The company’s cancer treatment pipeline currently includes five drug candidates progressing through six clinical trials – and progress has been announced in all programmes during the year. However, in the current tough market dynamics for biotech, like many other companies, BioInvent is valued under cash. BioStock contacted CEO Martin Welschof to talk about the progress during 2023 and to learn about his expectations for next year.Read the full interview with Martin Welschof at biostock.se:

    BioStock: BioInvent comments on breast cancer study progress

    BioInvent’s pipeline consists of five drug candidates advancing through six clinical trials. During the San Antonio Breast Cancer Symposium, BioInvent presented the first clinical data from one of these – the phase I/IIa trial of its second FcyRIIB-blocking antibody BI-1607. BioStock reached out to BioInvent’s Chief Medical Officer Andres McAllister for a comment.Read the article at biostock.se: https://www.biostock.se/en/2023/12/bioinvent-comments-on-breast-cancer-study-progress/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent is gearing up for clinical data presentations

    BioInvent marked a milestone in the third quarter of 2023 with the recruitment of the first patient for the BI-1808 single-agent phase IIa study. BI-1808, a potential novel checkpoint inhibitor, positions BioInvent at the forefront of harnessing the value of TNFR2 in cancer therapy. Meanwhile, the company is preparing for clinical data presentations of BI-1808 at SITC in San Diego, California and of BI-1607 at SABC in San Antonio, Texas.Read the article at biostock.se: https://www.biostock.se/en/2023/10/bioinvent-is-gearing-up-for-clinical-data-presentations/ This is a press release

    BioStock: BioInvent achieves research milestone in partnership with Exelixis

    BioInvent has achieved a research milestone in its partnership with Exelixis, focusing on the development of new antibodies for cancer therapy. This achievement unlocks a 1 million USD payment to BioInvent. The company's CEO Martin Welschof expressed satisfaction with the rapid progress of the collaboration while noting that it also serves as further validation for BioInvent's proprietary F.I.R.S.T. and n-CoDeR technologies.Read the article at biostock.se: https://www.biostock.se/en/2023/09/bioinvent-achieves-research-milestone-in-partnership-with-exelixis/ This is a press release

    BioStock: BioInvent soon has five drug candidates in six clinical studies

    BioInvent has made several advances in the second quarter of 2023, in particular with its lead drug candidate BI-1206. In addition to a strengthened pipeline, the company’s Q2 report highlights progress across the broad portfolio of drug candidates in clinical development. In the report, CEO Martin Welschof reminds that BioInvent will soon have five drug candidates in six parallel patient studies.Read the article at biostock.se: https://www.biostock.se/en/2023/09/bioinvent-soon-has-five-drug-candidates-in-six-clinical-studies/ This is a press release from BioStock - Connecting

    BioStock: BioInvent’s CMO comments on phase I/IIa data with BI-1808

    BioInvent’s phase I/IIa study with first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies has produced positive results. The strong interim safety data paves the way for the phase IIa part of the study. BioStock contacted the company’s CMO Andres McAllister to learn more.Read the interview with BioInvent's CMO Andres McAllister at biostock.se: https://www.biostock.se/en/2023/06/bioinvents-cmo-comments-on-phase-i-iia-data-with-bi-1808/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent ready for combination studies with BT-001

    BioInvent and its partner Transgene have reported positive results in the phase I/IIa study with the oncolytic virus BT-001. In 11 of the 18 included patients, the lesions were stabilised. In two patients, objective antitumour activity was also seen. This means that both partners can continue the evaluation as planned with the part of the study where BT-001 will be studied in combination with pembrolizumab.Read the article about BioInvent at biostock.se: https://www.biostock.se/en/2023/06/bioinvent-ready-for-combination-studies-with-bt-001/ This is a press release from BioStock -

    BioStock: BioInvent’s CFO on the company’s business strategy

    With a reported cash position of just over SEK 1.5 billion, BioInvent is very well-regarded compared to many life science companies of comparable size. The company’s CFO Stefan Ericsson tells BioStock what lies behind the company’s success. In particular, he highlights that the progress of the five ongoing clinical projects has increased the interest of domestic and international institutional investors.Read the full interview with Stefan Ericsson at biostock.se: https://www.biostock.se/en/2023/05/bioinvents-cfo-on-the-companys-business-strategy/ This is a press release from BioStock -

    BioStock: BioInvent reports clinical progress with BI-1206

    A fourth complete response has been observed in the phase I/II trial of BioInvent´s lead drug candidate BI-1206 in combination with rituximab in non-Hodgkin’s lymphoma. According to the company´s CEO Martin Welschof, this is very encouraging news for NHL patients who are in urgent need of improved treatment options.Read the article at biostock.se: https://www.biostock.se/en/2023/04/bioinvent-reports-clinical-progress-with-bi-1206/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: BioInvent’s CEO expects eventful 2023

    During 2022, biotech company BioInvent showed proof of attracting capital as well as new collaborations. The company also advanced several pipeline projects. BioInvent has thus entered 2023 with strong positioning, and several clinical updates are expected for the year. BioStock spoke with CEO Martin Welschof to find out what the year will mean for the company.Read the article about BioInvent at biostock.se: https://www.biostock.se/en/2023/03/bioinvents-ceo-expects-eventful-2023  This is a press release from

    BioStock: CMO gives insight on new BioInvent collaboration

    Having achieved a strong shareholder base, several important partnerships and a very successful capital raise last year, biotech company BioInvent has received yet another quality stamp. This one comes in the form of a collaboration agreement with the Leukemia & Lymphoma Society - whose blood cancer acceleration programme invests 3 MUSD in the company through a directed new issue. Going forward, BioInvent will get access to important knowledge and guidance from the patient organisation. BioStock contacted CMO Andres McAllister to get his comment.Read the article about BioInvent at biostock.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe